A genetically modified strain of E. coli bacteria, designed to display a specific protein, reduces signs of intestinal damage and inflammation in mice with chemically induced colitis, as shown by improved tissue scores and increased mucus-producing cells.

A genetically modified strain of E. coli bacteria, designed to produce a specific protein, reduces tumor formation by half to two-thirds in mice with intestinal inflammation and a genetic predisposition to colon cancer, when given alongside a cancer-promoting bacterial strain.

Engineered bacteria with ClbS protein on their surface reduce DNA damage caused by a bacterial toxin in human colon tissue models and colorectal cancer cells.

A genetically modified strain of E. coli, designed to produce a protein that neutralizes colibactin, significantly lowers the levels of a harmful E. coli strain in the intestines of mice.

Engineered bacteria displaying a specific protein called ClbS can reduce DNA damage caused by a toxin produced by other bacteria, with higher levels of the protein nearly eliminating the damage in human cells grown in the lab.